×
About 2,185 results

ALLMedicine™ Factor VII Center

Research & Reviews  733 results

Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of...
https://doi.org/10.1111/jth.15801
Journal of Thrombosis and Haemostasis : JTH; Hu Y, Repa A et. al.

Jun 25th, 2022 - Tissue factor (TF) is expressed in the adventitia of the vessel wall and also commonly present on extracellular vesicles (EVs) in normal body fluids. TF and activated coagulation factor (F) VII(a) together form the so-called extrinsic tenase compl...

Factor VII, EPCR, aPC Modulators: novel treatment for neuroinflammation.
https://doi.org/10.1186/s12974-022-02505-y 10.1111/j.1365-2141.2005.05753.x 10.1097/CCM.0b013e3181c98d21 10.1189/jlb.0607373 10.1016/j.virusres.2020.198070 10.1016/S1474-4422(15)70016-5 10.1016/S1474-4422(18)30394-6 10.1038/s41582-019-0231-z 10.3389/fneur.2019.00059 10.4081/ejh.2020.3109 10.4103/1673-5374.262568 10.1007/s00109-019-01837-2 10.1111/j.1538-7836.2005.01377.x 10.1089/neu.2015.4146 10.1371/journal.pone.0219453 10.1007/s12031-013-0200-8 10.3389/fneur.2018.01139 10.1002/glia.23714 10.1378/chest.124.3_suppl.26S 10.1523/JNEUROSCI.3485-08.2008 10.1177/1559325820917288 10.1056/NEJMoa1202290 10.1182/blood-2018-02-769026 10.1160/TH11-11-0766 10.3390/ijms21072422 10.1007/s12031-013-0072-y 10.1007/s10339-011-0430-z 10.1038/nprot.2013.155 10.1037/0735-7044.110.6.1321 10.1038/nmeth.2089 10.1038/s41598-017-14179-1 10.1161/ATVBAHA.116.308038 10.1007/s13311-018-0661-0 10.1172/JCI90606 10.1016/j.jneuroim.2005.09.012 10.3390/cells8101293 10.1161/01.RES.0000133680.87668.FA 10.1097/00007890-199560120-00026 10.3389/fnins.2020.00333 10.3389/fendo.2014.00067 10.1073/pnas.0810687106 10.1124/jpet.103.052100 10.1097/00001756-200205070-00022 10.3390/md13021026 10.1016/0014-5793(93)81341-V 10.1136/jnnp-2018-320106 10.1212/WNL.0000000000006321 10.1097/ALN.0000000000002130 10.1073/pnas.96.15.8721
Journal of Neuroinflammation; Golderman V, Ben-Shimon M et. al.

Jun 12th, 2022 - Inflammation and coagulation are linked and pathogenic in neuroinflammatory diseases. Protease-activated receptor 1 (PAR1) can be activated both by thrombin, inducing increased inflammation, and activated protein C (aPC), inducing decreased inflam...

First-in-Human PET Imaging of Tissue Factor in Patients with Primary and Metastatic Can...
https://doi.org/10.2967/jnumed.122.264068
Journal of Nuclear Medicine : Official Publication, Socie... Loft M, Christensen C et. al.

May 20th, 2022 - Tissue factor (TF) expression in cancers correlates with poor prognosis. Recently, the first TF-targeted therapy was approved by the US Food and Drug Administration for cervical cancer. To unfold the potential of TF-targeted therapies, correct str...

PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)
https://clinicaltrials.gov/ct2/show/NCT02074436

May 17th, 2022 - Study Treatments: Epsilon aminocaproic acid (EACA) vs. standard prophylactic platelet transfusions. Study Title: Randomized Trial of Epsilon Aminocaproic Acid versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients...

Evaluation of Coagulation Testing in Patients Undergoing Cardiac Surgery
https://clinicaltrials.gov/ct2/show/NCT02410473

May 12th, 2022 - Neonates, children with single ventricle congenital heart disease, and those undergoing multiple complex cardiac surgeries are at high risk of increased perioperative blood loss, and blood product transfusions. In addition, some of these patients ...

see more →

Guidelines  2 results

Damage control resuscitation in patients with severe traumatic hemorrhage: A practice m...
https://doi.org/10.1097/TA.0000000000001333
The Journal of Trauma and Acute Care Surgery; Cannon JW, Khan MA et. al.

Feb 23rd, 2017 - The resuscitation of severely injured bleeding patients has evolved into a multi-modal strategy termed damage control resuscitation (DCR). This guideline evaluates several aspects of DCR including the role of massive transfusion (MT) protocols, th...

Active management of the third stage of labour: prevention and treatment of postpartum ...
https://doi.org/10.1016/S1701-2163(16)34329-8
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Leduc D, Senikas V et. al.

Nov 28th, 2009 - To review the clinical aspects of postpartum hemorrhage (PPH) and provide guidelines to assist clinicians in the prevention and management of PPH. These guidelines are an update from the previous Society of Obstetricians and Gynaecologists of Cana...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  90 results

PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)
https://clinicaltrials.gov/ct2/show/NCT02074436

May 17th, 2022 - Study Treatments: Epsilon aminocaproic acid (EACA) vs. standard prophylactic platelet transfusions. Study Title: Randomized Trial of Epsilon Aminocaproic Acid versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients...

Evaluation of Coagulation Testing in Patients Undergoing Cardiac Surgery
https://clinicaltrials.gov/ct2/show/NCT02410473

May 12th, 2022 - Neonates, children with single ventricle congenital heart disease, and those undergoing multiple complex cardiac surgeries are at high risk of increased perioperative blood loss, and blood product transfusions. In addition, some of these patients ...

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
https://clinicaltrials.gov/ct2/show/NCT04563520

Apr 19th, 2022 - The previous standard of care for high titer antibody eradication in hemophilia A (HA) included a labor-intensive, immune tolerance induction (ITI) regimen administered with concomitant bypassing agent (BPA) prophylaxis, either daily recombinant a...

Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
https://clinicaltrials.gov/ct2/show/NCT02453542

Mar 31st, 2022 - Background The treatment of haemophilia A and B has been revolutionized by the use of factor concentrate, both as prophylaxis and to treat bleeding episodes (on-demand treatment). However, despite its advantages, repeated treatment with factor con...

Recombinant Factor VII for Intractable Postpartum Haemorrhage
https://clinicaltrials.gov/ct2/show/NCT05298826

Mar 28th, 2022 - Major postpartum haemorrhage is a dangerous complication that accounts for the highest maternal morbidity rate

see more →

News  44 results

Pharmacyclics Hopes to Break Through With Blood Cancer Drug Ibrutinib
https://www.onclive.com/view/pharmacyclics-hopes-to-break-through-with-blood-cancer-drug-ibrutinib

Jun 30th, 2020 - Sunnyvale, California-based Pharmacyclics has yet to lay claim to any FDA-approved therapeutics since it was formally incorporated in 1991, but that may very well change in the near future as a first-in-class drug for certain B-cell malignancies i...

FDA approves recombinant treatment for hemophilia A or B with inhibitors
https://www.mdedge.com/hematology-oncology/article/220097/bleeding-disorders/fda-approves-recombinant-treatment-hemophilia
Christopher Palmer

Apr 2nd, 2020 - The Food and Drug Administration has approved a new rabbit-derived recombinant analog of human coagulation factor VII (Sevenfact) for the treatment of hemophilia A or B, according to a release from the agency. The treatment’s approval is for use i.

Bleeding disorders don’t carry increased risks for patients undergoing endoscopy
https://www.mdedge.com/hematology-oncology/article/196316/bleeding-disorders/bleeding-disorders-dont-carry-increased-risks
Andrew D. Bowser

Mar 13th, 2019 - When managed by an experienced team, patients with inherited bleeding disorders undergoing gastrointestinal endoscopy are not at increased bleeding risk, according to researchers reporting the largest series of such patients to date. The postendos.

Can Magnesium Stop Bleeding in ICH, Improve Outcomes?
https://www.medscape.com/viewarticle/884699

Aug 25th, 2017 - Lower levels of magnesium on hospital admission for intracerebral hemorrhage (ICH) are associated with larger hematoma volumes and growth, as well as worse functional outcomes at 3 months, suggesting an important role of magnesium in coagulation a...

Clotting Protein May Not Improve Hemorrhagic Stroke Outcomes
https://www.mdedge.com/neurology/article/134452/stroke/clotting-protein-may-not-improve-hemorrhagic-stroke-outcomes

Mar 28th, 2017 - HOUSTON—Acute hemostatic treatment with a clotting protein does not improve short- or long-term outcomes in patients with intracerebral hemorrhage (ICH), according to research presented at the International Stroke Conference 2017. David Gladstone,.

see more →